AdAlta

Webinars

Updates

Home

Why Invest

Announcements

Lora

Bioshares 962 Adalta extract (1).pdf

A BIOSHARES feature article on progress of CAR-T cell therapy concludes in part that breakthroughs against solid tumours will likely generate larger deals; China will remain active in the CAR-T field; and this supports AdAlta’s strategy of seeking to license immune-oncology assets for solid cancers from China for use in western biotech markets including the US and Europe.

BIOSHARES has also penned an insightful article about AdAlta’s strategy to commercialise its suite of singe domain antibodies (i-bodies). The article highlights the important role two special purpose vehicles are playing in delivering this strategy. The first is AdSolis, which houses lead drug candidate AD-214 which is heading towards Phase II clinical trials. The second is the AdCella subsidiary executing an 'East to West Reverse Innovation Strategy & Business Model’ for cellular immunotherapies, harnessing Asia innovation, Australian capabilities and with AdAlta's i-body® platform.

BIOSHARES: Adalta Creates AdSolis and AdCella Subsidiaries